GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Earnings Power Value (EPV)

NVCT (Nuvectis Pharma) Earnings Power Value (EPV) : $1.00 (As of Sep24)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Earnings Power Value (EPV)?

As of Sep24, Nuvectis Pharma's earnings power value is $1.00. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Nuvectis Pharma Earnings Power Value (EPV) Historical Data

The historical data trend for Nuvectis Pharma's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Earnings Power Value (EPV) Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Earnings Power Value (EPV)
- - - -

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuvectis Pharma's Earnings Power Value (EPV)

For the Biotechnology subindustry, Nuvectis Pharma's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvectis Pharma's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Earnings Power Value (EPV) falls into.



Nuvectis Pharma Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.


Nuvectis Pharma  (NAS:NVCT) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Nuvectis Pharma Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Executives
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024